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1. Introduction 
Vasoactive intestinal polypeptide (VIP) might be 
involved in the regulation of pituitary function 
[l-4]. Some of the peptide action is probably effected 
at the level of pituitary cells, as suggested by its pres- 
ence at high concentration in the hypophyseal portal 
blood [S] and by the existence of a VIP-sensitive 
adenylate cyclase in rat pituitary gland [6,7]. In par- 
ticular, although the available experimental evidence 
is still incomplete and controversial, a physiological 
role of VIP in the direct control of prolactin (PRL) 
release has been envisaged [I ,3]. 
These results support this hypothesis and give 
some insight on the mechanisms of action of VIP on 
pituitary mammotroph cells. In fact, working on 
human PRL-secreting adenomas, i.e., on homogeneous 
populations of lnammotroph cells, we demonstrate 
that: 
(1) VIP stimulates the release of PRL from tissue 
fragments incubated in vitro; 
(2) A VIP-sensitive adenylate cyclase is present in 
these pituitary tumors. 
2. Experimental 
2.1. Materials 
Natural porcine VIP was kindly supplied by Profes- 
sor Mutt, Karolinska Institute& Stockholm. Adenosine- 
5’-triphosphate (ATP), adenosine-3’,5’-cyclic mono- 
phosphate (CAMP), creatine phosphate) creature phos- 
phokinase, guanosine-5’-triphosphate (GTP) and 
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ethylene glycol-bis {2-anlinoethylether) ~~~~~‘-te- 
traacetic acid (EGTA) were purchased from Sigma, 
St Louis, MO. [8-r4C]ATP and cyclic [8-3H]AMP 
were purchased from the Radiochemical Center, 
Amersham. PRL radioimmunoassay kit was supplied 
by Biodata-Serono, Rome. 
2.2. PRL release 
Pituitary adenomas were surgically removed from 
patients through the transsphenoidal route, placed in 
oxygenated Krebs Ringer bicarbonate medium con- 
taining glucose and amino acids (pH 7.4) (KRB) [8], 
and quickiy cut into small fragments of -1 mm3. 
Incubations were carried out at 37OC in a shaking 
bath first for two 1 h periods in plain KRB (6 frag- 
ments/ml) and then for 30 min in KRB with or with- 
out VIP (1 0m7 M). At the end of the final incubation, 
the media were collected, centrifuged at 105 000 X g 
for 60 min and stored at -2O’C until radioimmu~o- 
assay of PRL was performed according to [9]. Ade- 
noma fragments were homogenized and their protein 
content assayed according to [lo]. 
2.3. Adenylate cyclase assay 
Adenoma fragments, frozen immediately after 
surgery, were stored up to 10 days at -2O’C. Homoge- 
nization was performed in 20 vol. 1 mM Tris-ma- 
leate buffer (pH 7.4) by a glass-Teflon Potter homog- 
enizer. The enzyme assay was carried out either on 
the total homogenate, filtered through a nylon gauze, 
or on the crude membrane preparation obtained by 
centrifuging the homogenate at 20 000 X g for 10 min 
and resuspending the pellet in 1 mM Trismaleate 
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buffer at l--25 mg protein/ml. The assay mixture 
contained: Tris-maleate buffer (50 mM (pH 7.4)) 
[8-rJC]ATP (0.15 mM, 40 dpmjpmol), cyclic [8-3H]- 
AMP (I mM, 350 dpm~ntnol), creatine phosphate 
(7 mM), creatine phosphokinase (6.2 U/ml), MgS04 
(5 mM), ECTA and GTP (0.3 and 0.01 mM, respec- 
tively, unless specified differently), VIP, pituitary 
homogenate or membranes to 0.1 ml final vol. Isola- 
tion and measLlrement of cyclic [8-3H, 14C]AMP was 
performed according to f 1 I]. These experitnental 
conditions permitted correction for the effect of 
phosphodiesterases which in any case was almost 
negligible [ 121. 
3. Results 
The effect of 10e7 M VIP on in vitro PRL release 
was investigated in 3 different human prolactinomas. 
In all cases a significant stimulation was observed, 
with increases over the basal levels of 70-I 70% 
(table 1). 
The effect of VIP on adenylate cyclase was studied 
in 6 adenomas. In all of them the enzyme activity was 
stimulated, although the degree of this stimulation 
wasquite variable (20-I 19% at 10-6M VIP)(table 2). 
VIP was equally effective on both total homogenates 
and crude tnembrane preparations. Fig.1 illustrates 
the dose response relationship in one pituitary ade- 
noma. Half-maximal stimulation occurred at 4.5 X 
lo-’ M and the highest enzyme activation at 3 X 
10e6M VIP. At a higher concentration (10” M) the 
peptide elicited an inhibitory effect. The curves 
Table 1 
In vitro effect of VIP on PRL release from human PRL- 
secreting pituitary adenomas” 
Case pg PRL/mg protein lo increase P 
basal 10“ M VIP 
G.A. 3.32 k 0.45 5.77 + 0.15 14 <0.05 
P.C. 3.10 i 0.20 8.37 t 0.42 170 <O.Ol 
I.B. 2.61 f 0.10 6.32 i 0.30 142 <O.Ol 
a Values given are the means (? SE) of 2 determinations each 
carried out on duplicate incubation media 
VI? M 
Fig.1. Effect of different doses of VIP on adenylate cyclase 
activity in the crude membrane preparation (case LB.). 
Values given are the means of 3 determinations i- SE. 
Table 2 
VIP-sensitive adenylate cyclase in human PRL-secreting pituitary adenomasa 
Case Enzyme pmol cAMP/mg protem X mm % stimulation P 
prep. ---. -_.-.-._ 
Basal 1O-6 M VIP 
E.B. 13.65 I 0.52 19.10 * 0.43 
G.A.C 8.47 ?I 0.19 10.68 f 0.31 
M.L. $i 8.56 t 0.44 14.10 * 0.43 
22.90 + 2.22 40.00 + 1.40 
C.A. M d 13.87 + 2.00 30.36 i 0.92 
P.C. $ 38.90 t 1.20 46.64 i: 0.12 
I.B. 22.95 r 0.11 29.39 I 0.45 
a Values given are the means of 3 determinations I SE 
b H, total homogenate 
c In this case EGTA was 5 X low4 M 
d M, crude membrane preparation 
39.9 <0.005 
26.1 <O.Ol 
64.1 <0.005 
74.7 <0.005 
118.9 <0.005 
19.9 <O.OOl 
28.1 <o.oos 
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GTP, M 
Fig.2. Effect of GTP on basal (o-o) and VIP-stimulated Fig.3. Effect of EGTA on basal (o--o) and VIP-stimulated 
(o-0) adenylate cyclase activity in the crude membrane (0-m) adenylate cyclase activity in the total homogenate 
preparation (case M.L.). Values given are the means of 3 (case G.A.). Values given are the means of 3 determinations 
determinations k SE. f SE. 
obtained with the other tumors showed similar pat- 
terns. 
The effect of various doses of GTP on the basal 
and VIP-stimulated adenylate cyclase of a crude mem- 
brane preparation obtained from one tumor is shown 
in fig.2. GTP increased the basal activity considerably 
and the VIP-stimulated activity to an even higher 
degree. GTP was maximally effective at 10d5 M. 
When EGTA was added to the total homogenate, 
the basal activity remained almost unchanged at up to 
2 X IO4 M and was inhibited at 5 X IO4 M. In con- 
trast, the VIP-sensitive activity was markedly stimu- 
lated even by lower concentrations of EGTA (fig.3). 
This result suggests a role of Ca2+ in the regulation of 
the cyclase by the peptide. 
4. Discussion 
The results we have obtained clearly demonstrate 
lO+M 
EGTA, M 
that VIP promotes a significant increase of PRL release 
from human PRL-secreting adenomas through a direct 
action on the tumor mammotrophs, in agreement 
with results in non-human experimental models 
(normal rat hemipituitaries [l] and GH3jB6 rat PRL- 
secreting cell line 131). The adenoma tissue we used 
consisted essentially of a homogeneous PRL-secreting 
cell population; the homogeneity was routinely 
checked by histological examination and SDS-poly- 
acrylamide gel electrophoresis of homogenates (data 
not shown). Since we have demonstrated here that 
VIP activates adenylate cyclase in such a tissue, we 
can conclude that the VIP-sensitive enzyme is located 
in the adenomatous PRL-secreting cell. This con- 
clusion is also in line with a single prolactinoma study 
1131. 
The VIP-sensitive enzyme shows GTP and Ca*’ 
dependence. The same biochemical characteristics are 
displayed by the VIP-stimulated cyclase detected in 
normal rat pituitary gland [6]. 
161 
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The demonstration of a VIP-sensitive adenylate 
cyclase in the tumor mammotrophs raises the ques- 
tion as to whether the stimulating effect of the pep- 
tide on PRL release is mediated by an increase in the 
intracellular concentration of CAMP. The fact that a 
concentration of VIP (lo-’ M) which has a marked 
effect on PRL release does not stimulate adenylate 
cyclase might appear to be in contradiction with this 
hypothesis. However, this is not necessarily the case, 
because the sante discrepancy has been observed in 
other systems where the mediation of CAMP in elicit- 
ing the biological response is well established [14,15]. 
‘In contrast, the importance of the CAMP-adenylate 
cyclase system in PRL secretion is suggested on one 
hand, by the consistei~cy of our findings in all the 
tumors investigated, on the other hand, by our 
previous finding that dibutyryl-CAMP and theophyl- 
line markedly enhanced PRL release from adenorna 
fragments (unpublished results and [ 161). 
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